ASCO 2023 | Assessing endpoints for patients treated with vorasidenib versus placebo for glioblastoma

Karan Dixit, MD, Northwestern Memorial Hospital, Chicago, IL, summaries the primary and secondary endpoints of the INDIGO trial (NCT04164901) investigating the use of vorasidenib for treating glioblastoma. At the primary endpoint of this study, patients who were administered vorasidenib showed significant improvement in progression-free survival (PFS), compared with patients in the placebo cohort. Time to the next intervention (TTNI) acted as the secondary endpoint, which was not met in patients who received vorasidenib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.